Judy Chou, AltruBio CEO

Al­tru­Bio se­cures $225M for an up­dat­ed ver­sion of its ul­cer­a­tive col­i­tis drug

Bay Area and Taipei biotech Al­tru­Bio has raised $225 mil­lion in a Se­ries B to move for­ward its ex­per­i­men­tal drug for ul­cer­a­tive col­i­tis and oth­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.